$21.27
3.76% yesterday
Nasdaq, Nov 20, 10:00 pm CET
ISIN
US45249V1070
Symbol
ELVN

Imara Inc Stock price

$21.27
-0.85 3.84% 1M
+3.89 22.38% 6M
-1.23 5.47% YTD
-4.16 16.36% 1Y
+3.63 20.58% 3Y
-60.73 74.06% 5Y
-38.73 64.55% 10Y
-38.73 64.55% 20Y
Nasdaq, Closing price Thu, Nov 20 2025
-0.83 3.76%
ISIN
US45249V1070
Symbol
ELVN
Industry

Key metrics

Basic
Market capitalization
$1.3b
Enterprise Value
$771.8m
Net debt
positive
Cash
$490.5m
Shares outstanding
59.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | 154,365.3
EV/Sales
- | 96,636.3
EV/FCF
negative
P/B
2.6
Financial Health
Equity Ratio
95.1%
Return on Equity
-28.7%
ROCE
-23.4%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $8.5k
EBITDA
$-113.9m | $-125.2m
EBIT
$-114.2m | $-125.5m
Net Income
$-100.1m | $-117.1m
Free Cash Flow
$-70.6m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-16.6% | -20.1%
EBIT
-16.5% | -20.0%
Net Income
-20.7% | -31.6%
Free Cash Flow
2.6%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -1,473,913.6%
EBIT
-
Net
- | -1,378,537.4%
Free Cash Flow
-
More
EPS
$-1.9
FCF per Share
$-1.2
Short interest
18.7%
Employees
62
Rev per Employee
$0.0
Show more

Is Imara Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,048 stocks worldwide.

Imara Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a Imara Inc forecast:

15x Buy
94%
1x Hold
6%

Analyst Opinions

16 Analysts have issued a Imara Inc forecast:

Buy
94%
Hold
6%

Financial data from Imara Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 26 26
22% 22%
-
- Research and Development Expense 88 88
16% 16%
-
-114 -114
17% 17%
-
- Depreciation and Amortization 0.31 0.31
3% 3%
-
EBIT (Operating Income) EBIT -114 -114
17% 17%
-
Net Profit -100 -100
21% 21%
-

In millions USD.

Don't miss a Thing! We will send you all news about Imara Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Imara Inc Stock News

Positive
Seeking Alpha
3 days ago
Enliven Therapeutics remains overvalued relative to its early-stage pipeline progress and current financials. ELVN-001 shows promising safety and efficacy signals in heavily pretreated CML patients, with a pivotal phase 3 trial planned for 2026. ELVN is well-capitalized, with over four years of cash runway, but faces a competitive and relatively small CML market.
Neutral
PRNewsWire
8 days ago
Completed enrollment of the randomized Phase 1b cohorts of the ongoing ENABLE trial of ELVN-001 in CML Remains on track to initiate Phase 3 pivotal trial of ELVN-001 in 2026 Strong balance sheet with $478 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into the first half of 2029 BOULDER, Colo. , Nov. 12, 2025 /PRNewswire/ -- Enliven Therape...
Neutral
PRNewsWire
3 months ago
BOULDER, Colo. , Aug. 25, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced the Company will present data from its ENABLE Phase 1a/1b clinical trial of ELVN-001 in both an oral and a poster presentation at the Society of Hemat...
More Imara Inc News

Company Profile

Imara, Inc. engages in the development and commercialization of novel therapeutics to treat patients suffering from hemoglobinopathies. Its product candidate, IMR-687 is a highly selective and small molecule inhibitor of PDE9. The company was founded by James G. McArthur in 2016 and is headquartered in Cambridge, MA.

Head office United States
CEO Samuel Kintz
Employees 62
Founded 2019
Website www.enliventherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today